The FDA has approved Amneal Pharmaceuticals’ ( NASDAQ: AMRX) OTC Naloxone HCl nasal spray, a generic version of the opioid ...
Sun Pharmaceutical industries share price has declined 4-5% in 2 trading sessions following OAI status determined by the ...
Sun Pharma Advanced Research Company Ltd. (SPARC) on Wednesday announced that it is abandoning the Phase 2 study on Vodobatinib for Parkinson’s Disease. According to the company’s exchange ...
Shares of Sun Pharma Advanced Research Company (SPARC ... experts before taking any investment decisions. Advisory Alert: It has come to our attention that certain individuals are representing ...
Sun Pharma Advanced Research Company Ltd. announced the results of the interim analysis from the Proseek study, a global Phase 2 study in patients with early Parkinson’s Disease. The study ...
On April 10, Sun Pharma Advanced Research Company (SPARC) shares dropped 5% to reach the lower circuit following the Mumbai-based pharmaceutical company's announcement that it was giving up on its ...
One member of the FDA advisory committee was linked to hundreds of payments from Abbott totaling almost $200,000, according to the database maintained by the federal Department of Health and Human ...
Mumbai-based pharmaceutical company, Sun Pharma Advanced Research Company Ltd. (SPARC), said it was abandoning its Phase 2 study on Vodobatinib for Parkinson's. The study was designed to evaluate ...
the FDA increased screening and surveillance sampling or placed the associated company and product on Import Alert (IA) 99-47. Products listed on the Import Alert are subject to “Detention witho ...
It has picked Sun Pharma, JB Chemicals, Eris Lifesciences and Torrent Pharma as its top picks Dalal Street is all set to kick start the earnings season for the quarter ended March 2024.
Sensex at 75,000 : Reliance Industries, Tata Motors, Mahindra & Mahindra , Sun Pharmaceutical Industries, Maruti Suzuki, State Bank of India, Bharti Airtel, NTPC , Power Grid Corporation of India ...
Gland Pharma made a significant announcement on Monday regarding the FDA approval of Eribulin Mesylate Injection, 0.5 mg/mL Single Dose Vial. This drug, which is an anti-cancer medication ...